Education
About Us
Working with TipRanks
Follow Us
Dr. Reddy's Laboratories Ltd (RDY)
:RDY
RDY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.26 - $16.17
Previous CloseN/A
Volume378.64K
Average Volume (3M)880.45K
Market Cap
$11.73B
Enterprise Value$12.38B
Total Cash (Recent Filing)$57.91B
Total Debt (Recent Filing)$46.77B
Price to Earnings (P/E)17.6
Beta0.47
Next Earnings
Oct 24, 2025EPS Estimate
0.2Last Dividend Ex-Date
Jul 25, 2025Dividend Yield0.65%
Share Statistics
EPS (TTM)0.20
Shares Outstanding834,574,700
10 Day Avg. Volume1,095,380
30 Day Avg. Volume880,452
Financial Highlights & Ratios
PEG Ratio10.58
Price to Book (P/B)2.82
Price to Sales (P/S)2.89
P/FCF Ratio78.16
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue0.04
Enterprise Value/Gross Profit0.06
Enterprise Value/Ebitda0.13
Forecast
1Y Price Target
$16.00Price Target Upside14.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Dr Reddy's Laboratories News
RDY FAQ
What was Dr. Reddy's Laboratories Ltd’s price range in the past 12 months?
Dr. Reddy's Laboratories Ltd lowest stock price was $12.26 and its highest was $16.17 in the past 12 months.
What is Dr. Reddy's Laboratories Ltd’s market cap?
Dr. Reddy's Laboratories Ltd’s market cap is $11.73B.
When is Dr. Reddy's Laboratories Ltd’s upcoming earnings report date?
Dr. Reddy's Laboratories Ltd’s upcoming earnings report date is Oct 24, 2025 which is in 15 days.
How were Dr. Reddy's Laboratories Ltd’s earnings last quarter?
Dr. Reddy's Laboratories Ltd released its earnings results on Jul 29, 2025. The company reported $0.197 earnings per share for the quarter, missing the consensus estimate of $0.214 by -$0.017.
Is Dr. Reddy's Laboratories Ltd overvalued?
According to Wall Street analysts Dr. Reddy's Laboratories Ltd’s price is currently Undervalued.
Does Dr. Reddy's Laboratories Ltd pay dividends?
Dr. Reddy's Laboratories Ltd pays a Annually dividend of $0.091 which represents an annual dividend yield of 0.65%. See more information on Dr. Reddy's Laboratories Ltd dividends here
What is Dr. Reddy's Laboratories Ltd’s EPS estimate?
Dr. Reddy's Laboratories Ltd’s EPS estimate is 0.2.
How many shares outstanding does Dr. Reddy's Laboratories Ltd have?
Dr. Reddy's Laboratories Ltd has 834,574,700 shares outstanding.
What happened to Dr. Reddy's Laboratories Ltd’s price movement after its last earnings report?
Dr. Reddy's Laboratories Ltd reported an EPS of $0.197 in its last earnings report, missing expectations of $0.214. Following the earnings report the stock price went up 0.408%.
Which hedge fund is a major shareholder of Dr. Reddy's Laboratories Ltd?
Currently, no hedge funds are holding shares in RDY
Dr Reddy's Laboratories Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.00 (14.04% Upside)
$16.00 (14.04% Upside)
Blogger Sentiment
Bullish
RDY Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 508.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.21%
12-Months-Change
Fundamentals
Return on Equity
17.48%
Trailing 12-Months
Asset Growth
21.64%
Trailing 12-Months
Company Description
Dr. Reddy's Laboratories Ltd
Dr. Reddy's Laboratories (RDY) is a global pharmaceutical company based in India, engaged in the development and manufacturing of a wide range of pharmaceutical products, including generics, branded medications, and active pharmaceutical ingredients (APIs). The company operates across several therapeutic areas, including oncology, cardiovascular, and gastrointestinal, and serves markets in India, the United States, Europe, and other emerging economies. Dr. Reddy's is committed to providing affordable healthcare solutions through its innovative and high-quality products.
RDY Company Deck
RDY Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed performance with solid revenue growth in several segments and strategic advancements in biosimilars and environmental achievements. However, challenges remain with declines in the U.S. generics market and a decrease in gross profit margins, along with regulatory observations from the USFDA.View all RDY earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
1.05% Mutual Funds
3.09% Other Institutional Investors
95.07% Public Companies and
Individual Investors